Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma

Annals of Oncology

Volumn 22, Issue 4, 2011, Pages 787-793

  Bedikian, A Y ^a   DeConti, R C ^b   Conry, R ^c   Agarwala, S ^d   Papadopoulos, N ^a   Kim, K B ^a   Ernstoff, M ^e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c Southern Hematology and Oncology   (United States)

^d St Luke's Cancer Center   (United States)

^e DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Dacarbazine; DHA paclitaxel; Melanoma; Phase III trial

Indexed keywords

DACARBAZINE; DOCOSAHEXAENOIC ACID; DOCOSAHEXAENOIC ACID PLUS PACLITAXEL; PACLITAXEL; TAXOPREXIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD DISEASE; BODY WEIGHT; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPONATREMIA; IMMUNOPATHOLOGY; INFECTION; INFESTATION; INSOMNIA; LEUKOPENIA; LIMB PAIN; LYMPHATIC SYSTEM DISEASE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MELANOMA; MENTAL DISEASE; METABOLIC DISORDER; METASTASIS POTENTIAL; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NUTRITIONAL DISORDER; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; THORAX DISEASE; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING;

EID: 79953324540     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq438     Document Type: Article

References (26)

1. Anderson CM, Buzaid AC, Legha SS. Systemic treatments for advanced cutaneous melanoma. Oncology (Williston Park) 1995; 9: 1149-1158.
2. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
3. Avril MF, Aamdal S, Grob JJ et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004; 22: 1118-1125.
4. Bedikian AY, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24: 4738-4745.
5. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105-2116.
6. Allen IE, Kupelnick B, Kumashiro M et al. Efficacy of interleukin-2 in the treatment of metastatic melanoma. Cancer Ther 1998; 1: 168-173.
7. Buzaid AC, Legha SS, Winn R et al. Cisplatin (C), vinblastine (V), DTIC (D) (CVD) versus DTIC alone in metastatic melanoma: preliminary results phase III cancer community oncology program (CCOP). Proc Am Soc Clin Oncol 1993; 12: 389a (Abstr 1328).
8. Chapman PB, Einhorn LH, Meyers ML et al. Phase III multi-center randomized trial of the Dartmouth regimen versus DTIC in patients with metastatic melanoma. J Clin Oncol 1999; 17: 2745-2751.
9. Legha SS, Ring S, Papadopoulos N et al. A phase II trial of taxol in metastatic melanoma. Cancer 1990; 65: 2478-2481.
10. Einzig AI, Hochster H, Wiernik PH et al. A phase II study of taxol in patients with malignant melanoma. Invest New Drugs 1991; 9: 59-64.
11. Einzig AI, Wiernik PH, Wadler S et al. Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy. Invest New Drugs 1998; 16: 29-36.
12. Powderly J, Khan K, Richards J et al. A 2-stage controlled phase 1/2 study of STA-4783 in combination with paclitaxel in patients with advanced metastatic melanoma abstract. J Clin Oncol 2005; 23 (Suppl 16): 725 (Abstr 7561).
13. Wolff AC, Donehower RC, Carducci MK et al. Phase I study of DHA-paclitaxel, a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res 2003; 9: 3589-3597.
14. Data On File. Shirley, NY: Luitpold Pharmaceuticals, Inc.
15. Bradley MO, Webb NL, Anthony FH et al. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res 2001; 7: 3229-3238.
16. Payne M, Ellis P, Dunlop D et al. DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial. J Thorac Oncol 2006; 1(9): 984-990.
17. Jones RJ, Hawkins RE, Eatock MM et al. A phase II open-label study of DHApaclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemother Pharmacol 2008; 61(3): 435-441.
18. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648.
19. Burington BE, Emerson SS. Flexible implementations of group sequential stopping rules using constrained boundaries. Biometrics 2003; 59: 770-777.
20. Zimpfer-Rechner C, Hofmann U, Figl R et al. Randomized phase /I study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res 2003; 13(5): 531-536.
21. Bedikian AY, Plager C, Papadopoulos N et al. Phase I evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res 2004; 14: 63-66.
22. Walker L, Schalch H, King DM et al. Phase I trial of weekly paclitaxel in patients with advanced melanoma. Melanoma Res 2005; 15: 453-459.
23. nd line treatment for metastatic melanoma (MMM). Proc Am Soc Clin Oncol 2000; 19: 571a (Abstr #2249).
24. Middleton MR, Grob JJ, Aaronson N et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma [published correction appears in J Clin Oncol. 2000;18:2351]. J Clin Oncol 2000; 18: 158-166.
25. Patel PM, Suciu L, Mortier L et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV malignant melanoma: final results of the randomized phase III study (EORTC 18032). 33rd European Society of Medical Oncology (ESMO) Congress 2008 (AbstLBA8). 1 December 2008.
26. Homsi J, Bedikian AY, Kim KB et al. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. Melanoma Res 2009; 19: 238-242.